Tesamorelin

Egrifta

Grade A: Approved and proven

TL;DR: Tesamorelin (brand name Egrifta, Egrifta SV, and Egrifta WR) is an FDA-approved synthetic analogue of growth hormone-releasing hormone (GHRH) indicated specifically for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The approval rests on robust pivotal randomized controlled trials demonstrating statistically significant reductions in visceral adipose tissue as measured by CT scan; these are not merely observational studies. Meta-analyses of these RCTs confirm sustained visceral fat reduction with continued treatment and rebound on discontinuation, establishing the need for long-term use. Egrifta WR, a new formulation with simplified dosing, received FDA approval in 2025. The indication is narrowly defined and clinical evidence is specific to HIV-positive patients on antiretroviral therapy; evidence in other populations (e.g., general obesity, anti-aging) is not established through controlled trials. Evidence is Grade A for the approved indication.

Key Takeaways

Grade A: Approved and proven
FDA approved: FDA-approved (Egrifta; Egrifta WR approved 2025) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy; not approved for any other indication.
Compounding: Tesamorelin is FDA-approved (Egrifta/Egrifta SV/Egrifta WR) for HIV-associated lipodystrophy; the branded product is the appropriate source. FDA reclassified tesamorelin as a biologic, making 503A compounding of this substance impermissible under standard provisions. Off-label compounding for non-HIV indications (e.g., anti-aging, body composition) lacks regulatory authorization and falls outside the approved indication; clinical use should be confined to the labeled indication via the approved product.

Tesamorelin chemical structure — Structure via PubChem CID 16137828

Mechanism

Synthetic analogue of endogenous growth hormone-releasing hormone (GHRH) that binds pituitary GHRH receptors, stimulating pulsatile GH secretion and downstream IGF-1 production, which reduces visceral adiposity.

Evidence

Tesamorelin (brand name Egrifta, Egrifta SV, and Egrifta WR) is an FDA-approved synthetic analogue of growth hormone-releasing hormone (GHRH) indicated specifically for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The approval rests on robust pivotal randomized controlled trials demonstrating statistically significant reductions in visceral adipose tissue as measured by CT scan; these are not merely observational studies. Meta-analyses of these RCTs confirm sustained visceral fat reduction with continued treatment and rebound on discontinuation, establishing the need for long-term use. Egrifta WR, a new formulation with simplified dosing, received FDA approval in 2025. The indication is narrowly defined and clinical evidence is specific to HIV-positive patients on antiretroviral therapy; evidence in other populations (e.g., general obesity, anti-aging) is not established through controlled trials. Evidence is Grade A for the approved indication.

Safety and risks

Tesamorelin is contraindicated in patients with active malignancy; any preexisting malignancy must be inactive and treatment complete before initiating therapy, and treatment must be discontinued if malignancy recurs or is detected, given that IGF-1 is a growth factor and elevated levels may theoretically promote tumor progression. Tesamorelin stimulates GH secretion and raises serum IGF-1 and IGFBP-3; the long-term consequences of sustained IGF-1 elevation are unknown, and IGF-1 levels must be monitored during therapy with discontinuation considered for persistent supraphysiologic elevations. Common adverse events from pivotal RCTs include injection site reactions (erythema, pain, pruritus, induration), fluid retention with peripheral edema, arthralgia, joint stiffness, and myalgia. Tesamorelin may impair glucose tolerance and worsen hyperglycemia; glucose monitoring is warranted, and caution is required in patients with diabetes or prediabetes. Tesamorelin is contraindicated in pregnancy (risk of fetal harm) and should not be used in patients with hypersensitivity to tesamorelin or mannitol. HIV-positive patients receiving antiretroviral therapy already carry elevated background malignancy risk, which must be weighed when initiating therapy.

Interactions

Tesamorelin-induced GH and IGF-1 elevation may affect cytochrome P450 enzyme activity and alter metabolism of drugs metabolized by CYP enzymes (particularly CYP3A4-metabolized drugs such as cyclosporine, antiretrovirals, corticosteroids, and sex hormones); monitor for changes in efficacy or toxicity of concomitant medications. Glucocorticoids may suppress the GH response to tesamorelin; avoid concurrent use or use with caution.

Federal compounding status

FDA-approved drug as of 2026-06-02.

An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

Federal status only, from public FDA records. State pharmacy-board rules vary and are not covered here. This is regulatory reporting, not legal advice. All compounds.

Compounding legality

Tesamorelin is FDA-approved (Egrifta/Egrifta SV/Egrifta WR) for HIV-associated lipodystrophy; the branded product is the appropriate source. FDA reclassified tesamorelin as a biologic, making 503A compounding of this substance impermissible under standard provisions. Off-label compounding for non-HIV indications (e.g., anti-aging, body composition) lacks regulatory authorization and falls outside the approved indication; clinical use should be confined to the labeled indication via the approved product.

Sources

Tesamorelin is FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 1, 2026 by PeptideGrids editorial team (independently audited).